GSK (GSK) said Monday that the European Commission has approved Jemperli in combination with chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
This approval expands the previous indication for Jemperli plus chemotherapy in the European Union to include patients with mismatch repair proficient or microsatellite stable tumors, the company said.
The approval is based on results from the first part of the RUBY phase 3 trial, which showed a clinically meaningful and statistically significant overall survival benefit in the patients with a 31% reduction in risk of detah compared with chemotherapy alone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.